Bioxytran, Inc. recently announced promising results from a randomized, double-blind, placebo-controlled Phase 1b/2a clinical study of oral ProLectin-M in hospitalized patients with mild to moderate COVID-19. The study demonstrated that the highest evaluated dose of ProLectin-M (16,800 mg/day) led to statistically significant earlier viral clearance and faster clinical improvement by Day 5 compared to placebo, while maintaining a favorable safety profile.
By Day 7, viral clearance was observed across all study arms, aligning with the expected natural resolution of infection. This suggests that ProLectin-M may play a role in accelerating viral clearance rather than merely facilitating recovery. No serious adverse events were reported, reinforcing the drug’s tolerability.
Dr. Leslie Ajayi, Chief Medical Officer of Bioxytran, emphasized the potential of ProLectin-M as an oral antiviral with a unique mechanism, addressing critical gaps in current treatment paradigms. The findings advocate for further exploration of ProLectin-M in larger studies, potentially positioning it as a first-line therapy. As Bioxytran continues to develop this novel galectin-targeting approach, the results underscore the importance of innovative antiviral strategies in the ongoing fight against COVID-19 and other viral infections.
Open the full market picture for your next decision →
